Navigation Links
Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference
Date:11/18/2009

TUSTIN, Calif., Nov. 18 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that researchers presented positive data on progress in its federally funded preclinical viral hemorrhagic fever (VHF) program, confirming that its phosphatidylserine (PS)-targeting antibodies bind to VHF viruses and virally infected cells and increase survival in a model of lethal VHF infection. The data were presented at the 2009 Chemical and Biological Defense Science and Technology (CBD S&T) Conference in Dallas, Texas.

Researchers presented interim data from Peregrine's multi-year program to assess the company's PS-targeting antibodies as broad-spectrum agents for the treatment of viral hemorrhagic fevers, a potential biodefense threat. The studies evaluated the activity of Peregrine's PS-targeting antibodies against representatives of major VHF virus families. In these studies, researchers confirmed broad spectrum PS-targeting antibody binding to VHF viral particles and also demonstrated that Peregrine's PS-targeting antibodies bind to mammalian cells infected with hemorrhagic fever viruses. Initial pharmacokinetic and dosing studies also showed that the PS-targeting antibodies are sustainable in the blood at therapeutically relevant concentrations.

Importantly, initial antiviral efficacy studies reported at the conference were encouraging, showing that a single dose of a PS-targeting antibody increased the survival of hamsters infected with lethal doses of viruses from two different VHF virus families. Based on these positive findings, additional efficacy studies, including repeat dose and combination therapy studies, are now underway.

Dr. Amy Brideau-Andersen, head of Peregrine's preclinical antiviral program and lead author of the studies presented at the CBD S&T Confere
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
2. Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
3. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
4. Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
5. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
6. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
7. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
8. Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
9. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
10. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
11. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Madison, WI (PRWEB) January 22, 2015 Dr. ... at the 12th annual Scripps Natural Supplements Pre-Conference seminar on ... Supplements Conference is an annual continuing education conference for health ... 15th and included the topic of probiotics in health. Dr. ...
(Date:1/22/2015)... Jan. 22, 2015   Cypher Genomics, Inc., ... (NASDAQ: SQNM ), the leading molecular ... next generation noninvasive prenatal tests (NIPT). Through this ... called Mantis™, to advance analysis of clinically-relevant fetal ...
(Date:12/24/2014)... SILVER SPRING, Md. , Dec. 24, 2014  United ... that Medtronic, Inc. (NYSE: MDT ) has ... and Drug Administration (FDA) for the use of Medtronic,s ... a newly developed catheter) for use with United Therapeutics, ...
(Date:12/24/2014)... GMO corn cases filed across the United States, and ... being consolidated in a Kansas federal court for pretrial proceedings. ... Corn Litigation, MDL No. 2591 in the U.S. District Court ... GMO corn multidistrict litigation (MDL) has been handed over to ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... San Antonio (June 30, 2008) Researchers at The University ... Emerging Infectious Diseases and The University of Texas Health Science ... believed to play a role in controlling the early infectious ... bioterrorism agent that is the cause of tularemia. The findings ...
... Fla. -- Researchers have devised an inexpensive way to ... heat energy generated by the sun and other sources. ... Idaho National Laboratory, is the first step toward a ... materials. , While methods to convert the energy into ...
... /PRNewswire-FirstCall/ - Chromos Molecular,Systems Inc. ("Chromos" or ... of British Columbia has issued an interim ... in connection with the previously announced proposed,plan ... the,Company, Calyx Bio-Ventures Inc. ("Calyx"), a wholly-owned ...
Cached Biology Technology:UTSA/UTHSCSA publish results on bio-threat agent 2Flexible nanoantenna arrays capture abundant solar energy 2Flexible nanoantenna arrays capture abundant solar energy 3Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular 2Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular 3
(Date:12/19/2014)... and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) has announced ... - Apple/AuthenTec TMDR92 & Sapphire - Technology Report" ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition of AuthenTec ... with the iPhone 5S. It is currently the only ...
(Date:12/19/2014)... 18, 2014  23andMe, Inc., the leading personal genetics company, today ... in genetic ancestry of individuals from across the ... more than four hundred years ago, the United ... peoples from different continents. This study illuminates how American history ...
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 Based ... 5S, Samsung introduces for the first time a fingerprint ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... February 27, 2012 In a study published in ... the American Academy of Child and Adolescent Psychiatry , ... Children,s Healthcare of Atlanta, and Emory University School of ... cognitive and social disability in children with autism spectrum ...
... to be human in the face of emerging technologies ... hosts Emerge. An unparalleled campus-wide collaboration, Emerge unites ... designers to build, draw, write and rethink the future ... share. Leaders from industry and prominent authors and ...
... that there is a genetic component to intelligence, but a ... genes thought to be linked to intelligence are probably not ... roots may still be a long way off. ... Professor of Economics, and Christopher F. Chabris ,88, PhD ,99, ...
Cached Biology News:Eye-tracking reveals variability in successful social strategies for children with autism 2Emerge attracts futurists to collaborate with scientists, designers artists is redesign of future 2Emerge attracts futurists to collaborate with scientists, designers artists is redesign of future 3In the genes, but which ones? 2In the genes, but which ones? 3